DiscoverBaladoCritique - club de lecture médicalBC 061 – Resmetirom dans le traitement de la stéatohépatite liée à une dysfonction métabolique (étude MAESTRO-NASH)
BC 061 – Resmetirom dans le traitement de la stéatohépatite liée à une dysfonction métabolique (étude MAESTRO-NASH)

BC 061 – Resmetirom dans le traitement de la stéatohépatite liée à une dysfonction métabolique (étude MAESTRO-NASH)

Update: 2024-04-30
Share

Description

Dans cette 61e baladodiffusion, les Dr Luc Lanthier et Dusanka Grbic discutent de l’efficacité du resmetirom comme traitement de la stéatohépatite liée à une dysfonction métabolique, en plus de réviser la littérature médicale de janvier à mars 2024.


 


Quiz clinique (2 min 32), présentation principale (2 min 56), critique (25 min 50), autres articles (33 min 00), réponse au quiz clinique (35 min 35)


 


Référence principale


 


Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed PMID: 38324483.


 


Articles associés


 


Cusi K. Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH. N Engl J Med. 2024;390(6):559-561. PubMed PMID: 38324491.


 


Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-86. PubMed PMID: 37363821.


 


Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-835. PubMed PMID: 36727674.


 


Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161(5):1657-69. PubMed PMID: 34602251.


 


Byrne CD, Targher G, Tilg H. Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon. Gut. 2024;73(4):573-581. PubMed PMID: 38233199.


 


Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023;389(11):998-1008. PubMed PMID: 37356033.


 


Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-85. PubMed PMID: 20427778.


 


Chaudhuri D, Nei AM, Rochwerg B, Balk RA, Asehnoune K, Cadena R, et al. 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia. Crit Care Med. 2024;52(5):e219-e33. PubMed PMID: 38240492.


 


Hammond J, Fountaine RJ, Yunis C, Fleishaker D, Almas M, Bao W, et al. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. N Engl J Med. 2024;390(13):1186-1195. PubMed PMID: 38598573.


 


Autres articles d’intérêt récent


 


Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med. 2024;390(2):107-17. PubMed PMID: 37952132.


 


.Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390(2):132-42. PubMed PMID: 38197816.


 


Glal KAM, El-Haggar SM, Abdel-Salam SM, Mostafa TM. Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial. Am J Med. 2024;137(1):55-64. PubMed PMID: 37832758.


 


Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024;390(3):203-11. PubMed PMID: 38231621.


 


Hong SJ, Lee SJ, Suh Y, Yun KH, Kang TS, Shin S, et al. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial. Circulation. 2024;149(8):562-73. PubMed PMID: 37878786.


 


Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. N Engl J Med. 2024;390(8):701-11. PubMed PMID: 38329148.


 


Collaboration NCDRF. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-50. PubMed PMID: 38432237.


 


Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-99. PubMed PMID: 38407394.


 


Chung DC, Gray DM, 2nd, Singh H, Issaka RB, Raymond VM, Eagle C, et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024;390(11):973-83. PubMed PMID: 38477985.


 


Imperiale TF, Porter K, Zella J, Gagrat ZD, Olson MC, Statz S, et al. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. N Engl J Med. 2024;390(11):984-93. PubMed PMID: 38477986.


 


Guides de pratique


 


Bainey KR, Marquis-Gravel G, Belley-Cote E, Turgeon RD, Ackman ML, et al. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol. 2024;40(2):160-81. PubMed PMID: 38104631.


 


American Diabetes Association Professional Practice Committee. Summary of Revisions: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Supplement_1):S5-S10. PubMed PMID: 38078579.


 


Matthay MA, Arabi Y, Arroliga AC, Bernard G, Bersten AD, Brochard LJ, et al. A New Global Definition of Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2024;209(1):37-47. PubMed PMID: <span style="f

loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

BC 061 – Resmetirom dans le traitement de la stéatohépatite liée à une dysfonction métabolique (étude MAESTRO-NASH)

BC 061 – Resmetirom dans le traitement de la stéatohépatite liée à une dysfonction métabolique (étude MAESTRO-NASH)

Dr Luc Lanthier et collaborateurs